Connect with us

Hi, what are you looking for?

[t4b-ticker]
Home » World » Pfizer Seeks Conditional EU Authorisation For Covid-19 Pill

World

Pfizer Seeks Conditional EU Authorisation For Covid-19 Pill

Late last month, U.S. health regulators authorised the pill that patients will be able to take at home to ward off the worst effects of the virus.

Pfizer Seeks Conditional EU Authorisation For Covid-19 Pill
Pfizer's application to the EMA covers use of the pill to treat mild to moderate Covid 19 in patients aged 12 years and older who are at risk of developing severe symptoms of the disease. (File Photo)

The Hague: The European drug regulator said Monday it has started evaluating an application by Pfizer for its pill to treat the effects of Covid-19. The announcement comes as countries in much of the 27-nation bloc are reporting soaring numbers of infections as the highly transmissible omicron variant sweeps across the continent.

The European Medicines Agency said in a statement that it could decide within weeks whether to approve Pfizer’s application for a conditional marketing authorisation for the drug Paxlovid, “depending on whether the data submitted are sufficiently robust and whether further information is required to support the evaluation.”

Late last month, U.S. health regulators authorised the pill that patients will be able to take at home to ward off the worst effects of the virus. At the time, Pfizer said it had 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. The company said it expected to have 250,000 available in the U.S. by the end of January.

Pfizer’s application to the EMA covers use of the pill to treat mild to moderate Covid 19 in patients aged 12 years and older who are at risk of developing severe symptoms of the disease.

The EMA last month issued advice on use of the drug to EU nations that wanted to begin using it before official authorisation. The agency said it based its advice on a study of non-hospitalised, unvaccinated patients who had Covid-19 and at least one underlying condition that put them at risk of developing severe Covid-19 symptoms.

“These data showed that Paxlovid reduced the risk of hospitalisation and death when treatment started within five days of the start of symptoms,” the agency said.

ALSO READ: US Clears Second Covid-19 Pill As Merck Gets Approval Day after Pfizer

Read Full Article

Spotlight

Politics

The Congress in Punjab is yet to decide on who will be its face in the Assembly elections. Chief Minister Charanjit Singh Channi and...

Sports

Lakshya Sen from Almora won against Singaporean world champion Loh Kean Yew in a thrilling final 24-22, 21-17. He became the first Indian to...

India

Due to COVID-19 restrictions, the number of visitors to be substantially curtailed this year. We are looking at a range of 5000 to 8000...

World

The team led by researchers at the University of Exeter found that 13 per cent of people still exhibited clinically-relevant levels of virus after...

Videos

Dhanush in his shared statement, apart from revealing the shocking news also asked people to respect their decision and give them the needed privacy...

You May Also Like

Politics

A Lok Sabha MP since 2014, Mann is a popular face in Punjab and is one of the indisputable comedy kings. Mann has also...

Videos

Dhanush in his shared statement, apart from revealing the shocking news also asked people to respect their decision and give them the needed privacy...

Sports

Bharath Subramaniyam from Tamil Nadu became the 73rd Chess Grandmaster of India. He achieved the third and final Grandmaster Criterion at an event in...

India

Prime Minister Modi also highlighted India's role in providing vaccines to the world.

Advertisement